Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 4/20 | 0.38 |
| ▸ | HTR2A | P28223 | 4/20 | 0.38 |
| ▸ | PARP1 | P09874 | 1/20 | 0.38 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.38 |
| ▸ | TNK1 | Q13470 | 1/20 | 0.38 |
| ▸ | HTR1A | P08908 | 1/20 | 0.37 |
| ▸ | HTR7 | P34969 | 1/20 | 0.37 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | MTOR | P42345 | 1/20 | 0.36 |
| ▸ | RPTOR | Q8N122 | 1/20 | 0.36 |
| ▸ | MLST8 | Q9BVC4 | 1/20 | 0.36 |
| ▸ | DRD4 | P21917 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5530837 | 0.89 | MTOR (0.39) | DRD2HTR2APARP1TNK2TNK1 | |
| SCHEMBL5525246 | 0.87 | CYP3A4 (0.40) | DRD2HTR2APARP1TNK2TNK1 | |
| SCHEMBL5525437 | 0.83 | DRD4 (0.37) | DRD2HTR1AMAPTDRD4 | |
| SCHEMBL5528273 | 0.83 | MAPT (0.39) | DRD2HTR1AALDH1A1MAPTDRD4 | |
| SCHEMBL5529726 | 0.78 | CYP3A4 (0.42) | DRD2HTR2APARP1TNK2TNK1 | |
| SCHEMBL5525909 | 0.77 | ALDH1A1 (0.43) | ALDH1A1 | |
| SCHEMBL5529068 | 0.77 | TP53 (0.37) | DRD2HTR1AHTR7MTORRPTOR | |
| SCHEMBL5529630 | 0.76 | ALDH1A1 (0.42) | DRD2HTR2APARP1TNK2TNK1 | |
| SCHEMBL5530913 | 0.74 | KDM4E (0.44) | ALDH1A1 | |
| SCHEMBL5524887 | 0.73 | PARP1 (0.41) | DRD2HTR2APARP1TNK2TNK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070213339-A1 | Quinolone Carboxylic Acid Derivatives for Treatment of Hyperproliferative Conditions | BAYER PHARMACEUTICALS CORPORATION (US) | 2007-09-13 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070213339-A1 | Quinolone Carboxylic Acid Derivatives for Treatment of Hyperproliferative Conditions | TP53, RB1, HRAS | DRD2 3639/4885HTR2A 2650/4885PARP1 435/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.